ZYL-314

ZYL-314 is a novel small molecule drug candidate developed by Zylorion Health. It is specifically designed to target and activate the Brain-Derived Neurotrophic Factor (BDNF) and Tropomyosin receptor kinase B (TrkB) signaling pathways. By enhancing BDNF/TrkB signaling, ZYL-314 aims to promote neuroplasticity, neurogenesis, and neuronal survival, which are often compromised in neurodegenerative conditions. The compound is currently in preclinical development for the treatment of early-stage Alzheimer's Disease and Mild Cognitive Impairment (MCI). Notably, there is some discrepancy in historical documentation: while 2022 press releases described ZYL-314 as a second-generation psilocybin-based compound for mental health disorders, current company pipeline data explicitly identifies it as a BDNF/TrkB-targeting small molecule for cognitive decline, potentially reflecting a strategic pivot or a specific focus on the TrkB-mediated neuroplasticity associated with certain tryptamine derivatives.